Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
Cytotoxic T cells directed against leukemic blasts have been observed in patients with acute myeloid leukemia (AML). However, generation of efficient T-cell responses is hampered due to several factors that enable AML blasts to protect themselves from the patients immune system. Improved immune responses can be established by the differentiation of AML blasts into AML-derived dendritic cells (DC) thereby conserving their intrinsic leukemia specific antigens and obtaining full capacity to present these antigens to naive T cells. This review discusses increased immunogenicity of AML blasts by differentiation into AML-DC and describes ways to augment the AML-DC vaccination approach.
Houtenbos
Ilse
I
Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Westers
Theresia M
TM
Ossenkoppele
Gert J
GJ
van de Loosdrecht
Arjan A
AA
D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D019496:Cancer Vaccines; D002450:Cell Communication / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D019496:Cancer Vaccines